Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric R Pozsgai

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Applied and Environmental Microbiology|November 25, 2011
Modified mariner transposons for random inducible-expression insertions and transcriptional reporter fusion insertions in Bacillus subtilisEric R Pozsgai, Kris M Blair, Daniel B Kearns
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 13, 2017
Systemic AAV-Mediated β-Sarcoglycan Delivery Targeting Cardiac and Skeletal Muscle Ameliorates Histological and Functional Deficits in LGMD2E MiceEric R Pozsgai, Danielle A Griffin, Kristin N Heller, et al.
Human Gene Therapy|December 22, 2020
Preclinical Systemic Delivery of Adeno-Associated α-Sarcoglycan Gene Transfer for Limb-Girdle Muscular DystrophyDanielle A Griffin, Eric R Pozsgai, Kristin N Heller, et al.
Human Molecular Genetics|February 26, 2016
Defective membrane fusion and repair in Anoctamin5-deficient muscular dystrophyDanielle A Griffin, Ryan W Johnson, Jarred M Whitlock, et al.
Molecular Therapy. Methods & Clinical Development|February 23, 2023
Systemic γ-sarcoglycan AAV gene transfer results in dose-dependent correction of muscle deficits in the LGMD 2C/R5 mouse modelYoung-Eun Seo, Stephen H Baine, Amber N Kempton, et al.
Annals of Clinical and Translational Neurology|March 28, 2015
AAV.Dysferlin Overlap Vectors Restore Function in Dysferlinopathy Animal ModelsPatricia C Sondergaard, Danielle A Griffin, Eric R Pozsgai, et al.
Human Gene Therapy|July 15, 2017
Systemic Delivery of Dysferlin Overlap Vectors Provides Long-Term Gene Expression and Functional Improvement for DysferlinopathyRachael A Potter, Danielle A Griffin, Patricia C Sondergaard, et al.
Nature Medicine|January 4, 2024
Gene therapy with bidridistrogene xeboparvovec for limb-girdle muscular dystrophy type 2E/R4: phase 1/2 trial resultsJerry R Mendell, Eric R Pozsgai, Sarah Lewis, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Applied and Environmental Microbiology|November 25, 2011
Modified mariner transposons for random inducible-expression insertions and transcriptional reporter fusion insertions in Bacillus subtilisEric R Pozsgai, Kris M Blair, Daniel B Kearns
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 13, 2017
Systemic AAV-Mediated β-Sarcoglycan Delivery Targeting Cardiac and Skeletal Muscle Ameliorates Histological and Functional Deficits in LGMD2E MiceEric R Pozsgai, Danielle A Griffin, Kristin N Heller, et al.
Human Gene Therapy|December 22, 2020
Preclinical Systemic Delivery of Adeno-Associated α-Sarcoglycan Gene Transfer for Limb-Girdle Muscular DystrophyDanielle A Griffin, Eric R Pozsgai, Kristin N Heller, et al.
Human Molecular Genetics|February 26, 2016
Defective membrane fusion and repair in Anoctamin5-deficient muscular dystrophyDanielle A Griffin, Ryan W Johnson, Jarred M Whitlock, et al.
Molecular Therapy. Methods & Clinical Development|February 23, 2023
Systemic γ-sarcoglycan AAV gene transfer results in dose-dependent correction of muscle deficits in the LGMD 2C/R5 mouse modelYoung-Eun Seo, Stephen H Baine, Amber N Kempton, et al.
Annals of Clinical and Translational Neurology|March 28, 2015
AAV.Dysferlin Overlap Vectors Restore Function in Dysferlinopathy Animal ModelsPatricia C Sondergaard, Danielle A Griffin, Eric R Pozsgai, et al.
Human Gene Therapy|July 15, 2017
Systemic Delivery of Dysferlin Overlap Vectors Provides Long-Term Gene Expression and Functional Improvement for DysferlinopathyRachael A Potter, Danielle A Griffin, Patricia C Sondergaard, et al.
Nature Medicine|January 4, 2024
Gene therapy with bidridistrogene xeboparvovec for limb-girdle muscular dystrophy type 2E/R4: phase 1/2 trial resultsJerry R Mendell, Eric R Pozsgai, Sarah Lewis, et al.
Pageof 1